Takeda's Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial - Argus Press

Takeda's Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial  Argus Press

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Jan 29, 2019--Takeda Pharmaceutical Company Limited [ TSE:4502 / NYSE:TAK ] (“Takeda”) today ...



Comments

Post a Comment

Popular posts from this blog

SARS-CoV-2 virus may be shed for much longer periods by some infected patients, study shows - News-Medical.Net

Image
In a 38-year-old man who manifested mild symptoms of COVID-19 for 20 days, the novel coronavirus continued to be detected in his organism and to undergo mutations for 232 days. If he had not been given continuous medical care, maintained social distancing and worn a mask, he could have spread the virus throughout these seven months. The atypical case of infection by SARS-CoV-2 was part of a study involving 38 Brazilian patients followed on a weekly basis between April and November 2020 by researchers affiliated with the Pasteur-USP Scientific Platform, a partnership between France's Pasteur Institute, the University of Sao Paulo (USP) and Oswaldo Cruz Foundation (Fiocruz) in Brazil. The patients were followed until they tested negative twice or three times consecutively by RT-qPCR. The study was supported by FAPESP. An article reporting its findings is published in the journal Frontiers in Medicine . It serves as an alert regarding the risk of limiting quarantine for CO...
Read more